April 24, 2020 / 6:30 AM / a month ago

BRIEF-AstraZeneca Says Lynparza Shows Overall Survival In Prostate Cancer

April 24 (Reuters) - AstraZeneca Plc:

* ASTRAZENECA PLC - LYNPARZA SHOWS OVERALL SURVIVAL IN PROSTATE CANCER

* ASTRAZENECA - LYNPARZA DEMONSTRATED OS BENEFIT IN PHASE III PROFOUND TRIAL FOR BRCA1/2 OR ATM-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

* ASTRAZENECA - RESULTS FROM TRIAL SHOWED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN KEY SECONDARY ENDPOINT

* ASTRAZENECA - SAFETY AND TOLERABILITY PROFILE OF LYNPARZA WAS GENERALLY CONSISTENT WITH PREVIOUS TRIALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below